Probiotic combination therapy for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding a probiotic (a beneficial bacteria) to a standard chemo-immunotherapy combination can improve outcomes for people with metastatic colorectal cancer that hasn't responded to earlier treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have colorectal cancer that has spread to other parts of the body (metastatic) and is not removable by surgery.
- Your cancer is a type called MSS or pMMR, meaning it does not have certain genetic features that make immunotherapy more likely to work.
- You have already tried at least two different standard treatments for your cancer, and they didn't work.
- You have not taken antibiotics in the past 4 weeks.
- You do not have an autoimmune disease or take medications that suppress the immune system.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding a probiotic (Lactobacillus johnsonii) to a combination of chemotherapy and immunotherapy for people whose advanced solid tumors have grown despite prior immunotherapy. The goal is to see if the probiotic helps the treatment work better.
This study tests whether adding a fecal microbiota transplant (a way of putting healthy gut bacteria into your colon) to the standard first-line chemotherapy and targeted therapy can help control advanced colorectal cancer that cannot be surgically removed. The goal is to see if this combination works better than standard treatment alone.
This trial tests a new drug combined with standard chemotherapy and another medication for people with advanced colorectal cancer that has a specific genetic change (RAS mutation). It aims to see if the combination can help control the cancer better.
This study tests a new combination of drugs, including an immunotherapy and a targeted therapy, for colorectal cancer that has spread. The goal is to see if this combination can help shrink tumors or slow the cancer. It is designed for people who have not yet received treatment for metastatic disease.
This trial tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy and a targeted therapy (cetuximab) as the first treatment for colorectal cancer that has come back or spread. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests if taking a probiotic supplement along with your standard lung cancer treatment can help you live longer and respond better to therapy. It is for people with advanced non-small cell lung cancer who have not tried immunotherapy before.
Hear when a new Metastatic Colorectal Cancer (CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.